US Vitiligo Launch Lead, LITFULO

Job description

Litfulo (ritlecitinib) is a novel kinase inhibitor that received FDA approval in 2023 for the treatment of severe Alopecia Areata. Vitiligo, a disease that is the #1 cause of skin depigmentation worldwide, is the next indication in the brand’s pipeline and is expected to be filed in major markets later this year. The US Vitiligo Indication Launch Lead role represents a high-impact opportunity to shape the next phase of growth for LITFULO and the dermatology franchise. This role will lead cross-functional launch readiness and core brand strategy for a critical asset within Pfizer’s Inflammation & Immunology portfolio. The LITFULO Director, US Vitiligo Indication Launch Lead will be responsible for ensuring robust launch readiness and driving a successful market introduction by leading the strategic development and execution of HCP, DTC, and MGIDN strategies and initiatives. Success in this role requires strong cross-functional collaboration and the ability to influence and align stakeholders across global and US teams. This position requires demonstrated launch experience, strong strategic and analytical thinking, creativity, sound decision-making, and a proven ability to lead compl...